141 related articles for article (PubMed ID: 33480604)
1. The Usefulness of 4 Immunoperoxidase Stains Applied to Urinary Cytology Samples in the Pathologic Stage of Urothelial Carcinoma: A Study With Histologic Correlation.
Alabiad MA; Elderey MS; Shalaby AM; Nosery Y; Gobran MA
Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):422-432. PubMed ID: 33480604
[TBL] [Abstract][Full Text] [Related]
2. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
[TBL] [Abstract][Full Text] [Related]
3. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
[TBL] [Abstract][Full Text] [Related]
4. Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma.
Straub J; Strittmatter F; Karl A; Stief CG; Tritschler S
Urol Oncol; 2013 Oct; 31(7):1166-70. PubMed ID: 22300757
[TBL] [Abstract][Full Text] [Related]
5. Fascin stain as a potential marker of invasiveness in carcinomas of the urinary bladder: a retrospective study with biopsy and cytology correlation.
McKnight R; Cohen C; Siddiqui MT
Diagn Cytopathol; 2011 Sep; 39(9):635-40. PubMed ID: 20949550
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
7. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder.
Tong GX; Yee H; Chiriboga L; Hernandez O; Waisman J
Hum Pathol; 2005 Jul; 36(7):741-6. PubMed ID: 16084942
[TBL] [Abstract][Full Text] [Related]
8. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
9. Expression of cytokeratin 20 and CD44 protein in upper urinary tract transitional cell carcinoma: cytologic-histologic correlation.
Weaver EJ; McCue PA; Bagley DH; Kovatich AJ; Bibbo M
Anal Quant Cytol Histol; 2001 Oct; 23(5):339-44. PubMed ID: 11693559
[TBL] [Abstract][Full Text] [Related]
10. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
11. p16 INK4a overexpression and p16/Ki-67 dual labeling versus conventional urinary cytology in the evaluation of urothelial carcinoma.
Piaton E; Carré C; Advenier AS; Decaussin-Petrucci M; Mège-Lechevallier F; Lantier P; Granier G; Ruffion A
Cancer Cytopathol; 2014 Mar; 122(3):211-20. PubMed ID: 24302621
[TBL] [Abstract][Full Text] [Related]
12. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
13. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
[TBL] [Abstract][Full Text] [Related]
14. Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma.
Mai KT; Busca A; Belanger EC
Appl Immunohistochem Mol Morphol; 2017 Aug; 25(7):505-512. PubMed ID: 26990746
[TBL] [Abstract][Full Text] [Related]
15. Split-sample comparison of urothelial cells in ThinPrep and cytospin preparations in urinary cytology: Do we need to adjust The Paris System for Reporting Urinary Cytology criteria?
Richardson CJ; Pambuccian SE; Barkan GA
Cancer Cytopathol; 2020 Feb; 128(2):119-125. PubMed ID: 31774630
[TBL] [Abstract][Full Text] [Related]
16. The modern management of upper urinary tract urothelial cancer: tumour diagnosis, grading and staging.
Painter DJ; Timoney AG; Denton K; Alken P; Keeley FX
BJU Int; 2007 May; 99(5):973-7. PubMed ID: 17437428
[No Abstract] [Full Text] [Related]
17. IMP3 expression in urothelial carcinomas of the urinary bladder.
Ozdemir NO; Türk NS; Düzcan E
Turk Patoloji Derg; 2011 Jan; 27(1):31-7. PubMed ID: 21469424
[TBL] [Abstract][Full Text] [Related]
18. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
19. An institutional experience with The Paris System: A paradigm shift from ambiguous terminology to more objective criteria for reporting urine cytology.
Roy M; Kaushal S; Jain D; Seth A; Iyer VK; Mathur SR
Cytopathology; 2017 Dec; 28(6):509-515. PubMed ID: 28833848
[TBL] [Abstract][Full Text] [Related]
20. The application of the Johns Hopkins Hospital Template on urine cytology.
Wu HH; Redelman M; Chen S; Grignon DJ; Cramer HM
Diagn Cytopathol; 2015 Aug; 43(8):593-7. PubMed ID: 25721938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]